Home > Insider Trading > Filing (0001209191-16-126263)

Filing Details

Accession Number:: 0001209191-16-126263
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-06-07 16:38:00
Reporting Period:: 2016-06-07

Filing Date:: 2016-06-07
Accepted Time:: 2016-06-07 16:38:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1539029	Clearside Biomedical Inc.	CLSD	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1208570	Jr B Kenneth Lee	C/O Hatteras Ventures 280 S. Mangum St., Suite 350 Durham NC 27701	No	No	Yes	No
1219890	Alexander Robert Ingram	C/O Hatteras Ventures 280 S. Mangum St., Suite 350 Durham NC 27701	No	No	Yes	No
1291262	Md Douglas Reed	C/O Hatteras Ventures 280 S. Mangum St., Suite 350 Durham NC 27701	No	No	Yes	No
1390733	Hatteras Ventures Partners Iii Lp	280 S. Mangum St., Suite 350 Durham NC 27701	No	No	Yes	No
1390738	Hatteras Venture Affiliates Iii Lp	280 S. Mangum St., Suite 350 Durham NC 27701	No	No	Yes	No
1592380	Clay Thorp	C/O Hatteras Ventures 280 S. Mangum St., Suite 350 Durham NC 27701	Yes	No	Yes	No
1674107	John Crumpler	C/O Hatteras Ventures 280 S. Mangum St., Suite 350 Durham NC 27701	No	No	Yes	No
1674177	Hatteras Venture Advisors Iii, Llc	280 S. Mangum St., Suite 350 Durham NC 27701	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-06-07	1,598,219	$0.00	1,654,242	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2016-06-07	21,705	$0.02	1,675,947	No	4	X	Indirect	See Footnotes
Common Stock	Disposition	2016-06-07	69	$7.00	1,675,878	No	4	S	Indirect	See Footnotes
Common Stock	Acquisiton	2016-06-07	107,142	$7.00	1,783,020	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	X	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2016-06-07	2,035,907	$0.00	925,411	$0.00
Common Stock	Series A-1 Preferred Stock	Disposition	2016-06-07	689,388	$0.00	313,357	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-06-07	432,940	$0.00	196,790	$0.00
Common Stock	Series C Preferred Stock	Disposition	2016-06-07	337,898	$0.00	162,661	$0.00
Common Stock	Warrant to Purchase Common Stock (right to buy)	Disposition	2016-06-07	19,900	$0.00	19,900	$0.02
Common Stock	Warrant to Purchase Common Stock (right to buy)	Disposition	2016-06-07	1,805	$0.00	1,805	$0.02

Exercise Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
	No	4	C	Indirect
	No	4	C	Indirect
	No	4	C	Indirect
	No	4	C	Indirect
2014-04-28	No	4	X	Indirect
2014-04-28	No	4	X	Indirect

Footnotes

The total represents shares received upon conversion of shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock automatically converted into 0.454545 shares of the Issuer's common stock, and each share of Series C Preferred Stock automatically converted into 0.4814 shares of the Issuer's common stock. The Preferred Stock had no expiration date.
The reportable securities are owned directly by Hatteras Venture Partners III, LP ("HVP") and Hatteras Venture Affiliates III, LP ("HVA"). Hatteras Venture Advisors III, LLC is the general partner of HVP and HVA (the "GP"). The shares directly held by HVP and HVA are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP and HVA. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
On June 7, 2016, HVP and HVA exercised warrants to purchase an aggregate of 21,705 shares of Issuer's common stock for $0.022 per share. HVP and HVA paid the exercise price on a cashless basis, resulting in the Issuer's withholding of an aggregate of 69 of the warrant shares to pay the exercise price andissuing to the reporting person the remaining 21,636 shares.
HVP holds 1,634,603 shares and HVA holds 148,417 shares of the Issuer's Common Stock directly.
HVP held 1,866,418 shares and HVA held 169,489 shares of the Issuer's Series A Preferred Stock directly
HVP held 631,997 shares and HVA held 57,391 shares of the Issuer's Series A-1 Preferred Stock directly.
HVP held 396,920 shares and HVA held 36,020 shares of the Issuer's Series B Preferred Stock directly.
HVP held 309,768 shares and HVA held 28,130 shares of the Issuer's Series C Preferred Stock directly.
This warrant would have expired upon the closing of the Issuer's initial public offering.
The reportable securities were owned directly by HVP.
The reportable securities are owned directly by HVA.